Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CCR6 | P51684 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.67 |
| ▸ | MAOA | P21397 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276739 | 0.91 | KMT2A (0.79) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL14181848 | 0.89 | KMT2A (0.71) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL8956322 | 0.89 | ALDH1A1 (0.94) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL132620 | 0.86 | ALDH1A1 (1.00) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL9470190 | 0.84 | ALDH1A1 (0.94) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL28299815 | 0.83 | ALDH1A1 (0.68) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL1310574 | 0.83 | GAA (0.78) | ALDH1A1CYP3A4RAB9AMAPTNPC1 | |
| Tetramethylammonium Ion SCHEMBL28514624 | 0.82 | ALDH1A1 (0.81) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL9243020 | 0.82 | ALDH1A1 (0.81) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A | |
| SCHEMBL11674611 | 0.82 | KMT2A (0.75) | ALDH1A1CYP3A4TAS2R38HSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113271941-B | Urea derivatives for the treatment and/or prophylaxis of cancer | 法国国家科学研究中心 | 2024-09-20 | — | — | CN | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
| US-10253256-B2 | Use of sulfur and selenium compounds as precursors to nanostructured materials | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-09 | — | — | US | disclosed |
| US-20160237345-A1 | USE OF SULFUR AND SELENIUM COMPOUNDS AS PRECURSORS TO NANOSTRUCTURED MATERIALS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-18 | — | — | US | disclosed |
| EP-3049370-A1 | USE OF SULFUR AND SELENIUM COMPOUNDS AS PRECURSORS TO NANOSTRUCTURED MATERIALS | The Trustees of Columbia University in the City of New York (US) | 2016-08-03 | — | — | EP | disclosed |
| CN-101129295-B | There is the binary initiator system of good storage stability and especially suitable for acidic system | HERAEUS KULZER GMBH (DE) | 2016-02-10 | — | — | CN | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| CN-101129295-A | 2-component initiator system (amine free) with storage stability and especially suitable for acidic systems | HERAEUS KULZER GMBH (DE) | 2008-02-27 | — | — | CN | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253256-B2 | Use of sulfur and selenium compounds as precursors to nanostructured materials | SCLY, TST, SOD1 | ALDH1A1 1898/4885CYP3A4 3039/4885TAS2R38 4184/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | ALDH1A1 639/4885CYP3A4 4850/4885TAS2R38 105/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | ALDH1A1 1144/4885CYP3A4 1914/4885TAS2R38 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.